CSAM Medscinet U.K. Ltd - Period Ending 2021-12-31

CSAM Medscinet U.K. Ltd - Period Ending 2021-12-31


CSAM Medscinet U.K. Ltd 05948933 false 2021-05-01 2021-12-31 2021-12-31 The principal activity of the company is the provision of internet based medical applications Digita Accounts Production Advanced 6.26.9041.0 true 05948933 2021-05-01 2021-12-31 05948933 2021-12-31 05948933 bus:OrdinaryShareClass1 2021-12-31 05948933 core:RetainedEarningsAccumulatedLosses 2021-12-31 05948933 core:ShareCapital 2021-12-31 05948933 core:CurrentFinancialInstruments core:WithinOneYear 2021-12-31 05948933 core:FurnitureFittingsToolsEquipment 2021-12-31 05948933 bus:SmallEntities 2021-05-01 2021-12-31 05948933 bus:AuditExemptWithAccountantsReport 2021-05-01 2021-12-31 05948933 bus:AbridgedAccounts 2021-05-01 2021-12-31 05948933 bus:SmallCompaniesRegimeForAccounts 2021-05-01 2021-12-31 05948933 bus:RegisteredOffice 2021-05-01 2021-12-31 05948933 bus:Director1 2021-05-01 2021-12-31 05948933 bus:Director3 2021-05-01 2021-12-31 05948933 bus:OrdinaryShareClass1 2021-05-01 2021-12-31 05948933 bus:PrivateLimitedCompanyLtd 2021-05-01 2021-12-31 05948933 bus:Agent1 2021-05-01 2021-12-31 05948933 core:FurnitureFittings 2021-05-01 2021-12-31 05948933 core:FurnitureFittingsToolsEquipment 2021-05-01 2021-12-31 05948933 core:ParentEntities 2021-05-01 2021-12-31 05948933 countries:UnitedKingdom 2021-05-01 2021-12-31 05948933 2021-04-30 05948933 core:FurnitureFittingsToolsEquipment 2021-04-30 05948933 2020-05-01 2021-04-30 05948933 2021-04-30 05948933 bus:OrdinaryShareClass1 2021-04-30 05948933 core:RetainedEarningsAccumulatedLosses 2021-04-30 05948933 core:ShareCapital 2021-04-30 05948933 core:CurrentFinancialInstruments core:WithinOneYear 2021-04-30 05948933 core:FurnitureFittingsToolsEquipment 2021-04-30 iso4217:GBP xbrli:pure xbrli:shares

Registration number: 05948933

CSAM Medscinet U.K. Ltd

Filleted Annual Report and Unaudited Abridged Financial Statements

for the Period from 1 May 2021 to 31 December 2021

 

CSAM Medscinet U.K. Ltd

Contents

Company Information

1

Accountants' Report

2

Abridged Balance Sheet

3 to 4

Notes to the Unaudited Abridged Financial Statements

5 to 8

 

CSAM Medscinet U.K. Ltd

Company Information




 

Directors

Mr S Flatby

Mr E T Bonnevie

Registered office

The White Building
33 Kings Road
Reading
RG1 3AR

Accountants

HSJ Accountants Ltd
Severn House
Hazell Drive
Newport
South Wales
NP10 8FY

 

Accountants' Report to the Board of Directors on the Preparation of the Unaudited Statutory Accounts of
CSAM Medscinet U.K. Ltd
for the Period Ended 31 December 2021

As described on the balance sheet you are responsible for the compilation of the accounts for the period ended 31 December 2021, as set out on pages 3 to 8, and you consider that the company is exempt from an audit. In accordance with your instructions we have compiled the unaudited accounts from the accounting records and from information and explanations supplied to us.














HSJ Accountants Ltd
Severn House
Hazell Drive
Newport
South Wales
NP10 8FY

28 January 2022

 

CSAM Medscinet U.K. Ltd

(Registration number: 05948933)
Abridged Balance Sheet as at 31 December 2021

Note

2021
£

2021
£

Fixed assets

 

Tangible assets

4

3,089

3,837

Current assets

 

Debtors

129,748

67,121

Cash at bank and in hand

 

208,424

194,858

 

338,172

261,979

Prepayments and accrued income

 

1,093

2,016

Creditors: Amounts falling due within one year

(38,534)

(22,471)

Net current assets

 

300,731

241,524

Total assets less current liabilities

 

303,820

245,361

Accruals and deferred income

 

(110,878)

(77,686)

Net assets

 

192,942

167,675

Capital and reserves

 

Called up share capital

5

1,000

1,000

Profit and loss account

191,942

166,675

Total equity

 

192,942

167,675

 

CSAM Medscinet U.K. Ltd

(Registration number: 05948933)
Abridged Balance Sheet as at 31 December 2021

For the financial period ending 31 December 2021 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

The members have not required the company to obtain an audit of its accounts for the period in question in accordance with section 476; and

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime and the option not to file the Profit and Loss Account has been taken.

All of the company’s members have consented to the preparation of an Abridged Balance Sheet in accordance with Section 444(2A) of the Companies Act 2006.

Approved and authorised by the Board on 28 January 2022 and signed on its behalf by:
 

.........................................

Mr S Flatby
Director

.........................................

Mr E T Bonnevie
Director

 

CSAM Medscinet U.K. Ltd

Notes to the Unaudited Abridged Financial Statements for the Period from 1 May 2021 to 31 December 2021

1

General information

The company registration number is: 05948933

The company is a private company limited by share capital, incorporated in United Kingdom.

The address of its registered office is:
The White Building
33 Kings Road
Reading
RG1 3AR

These financial statements were authorised for issue by the Board on 28 January 2022.

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These abridged financial statements were prepared in accordance with Financial Reporting Standard 102 section 1A 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.

Basis of preparation

These abridged financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Foreign currency transactions and balances

Transactions in foreign currencies are initially recorded at the functional currency rate prevailing at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are retranslated into the respective functional currency of the entity at the rates prevailing on the reporting period date. Non-monetary items carried at fair value that are denominated in foreign currencies are retranslated at the rate on the date when the fair value is re-measured.

Non-monetary items measured in terms of historical cost in a foreign currency are not retranslated.

Tax

The tax expense for the period comprises current tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

 

CSAM Medscinet U.K. Ltd

Notes to the Unaudited Abridged Financial Statements for the Period from 1 May 2021 to 31 December 2021

Tangible assets

Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class

Depreciation method and rate

Furniture, fittings and equipment

15% Straight line

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

 

CSAM Medscinet U.K. Ltd

Notes to the Unaudited Abridged Financial Statements for the Period from 1 May 2021 to 31 December 2021

Borrowings

Interest-bearing borrowings are initially recorded at fair value, net of transaction costs. Interest-bearing borrowings are subsequently carried at amortised cost, with the difference between the proceeds, net of transaction costs, and the amount due on redemption being recognised as a charge to the Profit and Loss Account over the period of the relevant borrowing.

Interest expense is recognised on the basis of the effective interest method and is included in interest payable and similar charges.

Borrowings are classified as current liabilities unless the company has an unconditional right to defer settlement of the liability for at least twelve months after the reporting date.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Defined contribution pension obligation

A defined contribution plan is a pension plan under which fixed contributions are paid into a pension fund and the company has no legal or constructive obligation to pay further contributions even if the fund does not hold sufficient assets to pay all employees the benefits relating to employee service in the current and prior periods.

Contributions to defined contribution plans are recognised as employee benefit expense when they are due. If contribution payments exceed the contribution due for service, the excess is recognised as a prepayment.

3

Staff numbers

The average number of persons employed by the company (including directors) during the period, was 3 (2021 - 4).

 

CSAM Medscinet U.K. Ltd

Notes to the Unaudited Abridged Financial Statements for the Period from 1 May 2021 to 31 December 2021

4

Tangible assets

Furniture, fittings and equipment
 £

Total
£

Cost or valuation

At 1 May 2021

8,291

8,291

Disposals

(304)

(304)

At 31 December 2021

7,987

7,987

Depreciation

At 1 May 2021

4,454

4,454

Charge for the period

729

729

Eliminated on disposal

(285)

(285)

At 31 December 2021

4,898

4,898

Carrying amount

At 31 December 2021

3,089

3,089

At 30 April 2021

3,837

3,837

5

Share capital

Allotted, called up and fully paid shares

 

2021

2021

 

No.

£

No.

£

Ordinary of £1 each

1,000

1,000

1,000

1,000

         

6

Related party transactions

Summary of transactions with parent

MedSciNet AB
 During the year MedSciNet U.K. Ltd paid dividends to its parent company MedSciNet AB totalling £nil (2021 - £nil). MedSciNet AB charged MedSciNet U.K. Ltd £nil (2021 - £nil) for running UK computer applications and a virtual server.